How are pharmacovigilance and the DEA connected?

Pharmacovigilance and the DEA are connected through their shared emphasis on monitoring the safety and effectiveness of medications after they have been brought to market. Pharmacovigilance specifically deals with the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems, ensuring that any safety concerns related to medications are identified and addressed promptly to safeguard public health.

The DEA, while primarily focused on the regulation and control of controlled substances, also plays a role in monitoring the use and potential misuse of medications that may have a high risk for abuse or dependency. This overlap in responsibilities means that both entities contribute to the overarching goal of ensuring medication safety in the public sphere, albeit from different angles.

In contrast, the other options do not accurately capture this relationship. The focus on cost-effectiveness, drug manufacturing, and financial distribution aspects are not the central concern for either entity when it comes to their regulatory and monitoring activities.